Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 16, Issue 3, 2018

Background: Preeclampsia (PE) is a disorder of pregnancy characterised by persistent high blood pressure and proteinuria, which is usually detected after 20 weeks gestation. The pathophysiological mechanisms that underlie the pathogenesis of PE are unclear; although oxidative stress (OS), abnormal placental angiogenesis and endothelial dysfunction are reported to be contributing factors. Despite the synergistic roles Read More

Background: Drug addiction is a major health problem with limited treatment methods. Nowadays, the application of nanotechnology in the diagnosis and treatment of various diseases, such as drug abuse, is increasing. This emerging area of nanotechnology, with its rapid advances in science, opens new horizons in medical science and illness treatment. Nanotechnology research plays an important role in treatment an Read More

Background: A patient-focused approach to treatment, where individual characteristics provide the selection of optimal medication strategy for a particular patient, is the trend of current clinical therapy. An application of advanced “omics” technologies, which enable to detect the inter-individual variability in genomic, transcriptomic, proteomic, and metabolomic levels is a perspective way to achieve such personalization Read More

Background: Metformin is recommended in most clinical guidelines as a firstline oral anti-hyperglycemic drug to treat type 2 diabetes. Despite its effectiveness as an anti-hyperglycemic agent, certain genetic variants and conditions may cause metformin accumulation in the body and lead to lactic acidosis- a condition commonly known as Metformin Associated Lactic Acidosis (MALA). Though the incidence of MALA is relatively Read More

Background: Tuberculosis is one of the most prevalent infectious diseases. Treatment of tuberculosis requires treatment for a long duration with a combination of drugs such as Isoniazid, Rifampicin, Pyrazinamide and Ethambutol. Certain subsets of the population are more susceptible to adverse effects of treatment with isoniazid. Identification of the related genetic polymorphisms will enable Personalized Medication with Read More

Background: Paraoxonase is a calcium dependent enzyme which is bound to high density lipoprotein and acts primarily by inhibiting low density lipoprotein oxidation. Its activity is modulated by PON1 polymorphism. Objective: In the present case control study we determined the genotype frequencies of PON1 Q192R and L55M in Indian population and the association between PON activity and lipid markers in patients with c Read More